Cost Reduction
Proprietary technology reduces manufacturing costs by over 70%

Speed to Treatment
Manufacturing time cut from 4-6 weeks to just 2-3 days, getting therapy to patients faster

Vertical Integration
In-house viral vector production eliminates dependency on third parties, reduces supply chain risks and integrates three different business sectors into one business model

Global Scalability
Manufacturing facilities in USA and India enable worldwide accessibility and market penetration

Multi-revenue streams
MedTherapy’s integrated business model has two different Business Units:      
Contract MANUFACTURING and developing our own patented GENE THERAPY PRODUCTS

CANADA:

• Government of Canada: National Research Council

INDIA:

• TATA SONS
• Government of India: Institute of Genomics-CSIR, New Delhi
• Government of India: National Institute of Immunology, New Delhi
• Government of India: National Institute of Biologicals, Noida, U.P.
• Blood Bank Organization, New Delhi
• Artemis Hospital, Gurgaon, Haryana
• Jaypee Hospital, NOIDA
• Government Institute of Medical Sciences
• Post Graduate Institute of Medical Sciences
• All India Institute of Medical Sciences

AFRICA:

• Government of Uganda Joint Clinical Research Centre (JCRC), Uganda

Bikash Verma, MD, DVM, MS MVSc – Chief Executive Officer & Chief Medical Officer

Boston-based renowned physician, scientist and academician who has led several pioneering global health endeavors through his tenures both in academia as well as in the biotechnology industry. Prior to leading MedTherapy, was the Medical Director at Harvard Medical School serving as a faculty and currently remains affiliated with. Previously served as the Chief Medical Officer and Medical Director at Novartis, GSK and Aurora Biopharmaceutical. President of Boston-based International Health Organization (IHO) which works in partnership with Harvard University for global health. Successfully led more than 25 clinical trials in US and globally leading to FDA registration, approval and commercial success in areas of immunology, oncology and immuno-oncology, in particular gene therapies with CAR-T. Holds multi-disciplinary and interdisciplinary specializations in three medical fields including cancer, immunology, and preventive medicine which he accomplished through doctoral degrees in medicine (MD) as well as in veterinary medicine (DVM); master’s degrees in Cancer (MS) and in preventive medicine (MVSc); and post-doctoral fellowships in immunology, completed at University of Massachusetts and affiliated hospitals, University of Illinois, S Illinois University, Birsa University, International School of Medicine, and Tufts University, among others. Serves on the board of several national and international institutions, charitable organizations, journals and biotech companies. Received several national and international awards and recognition for his accomplishments in medicine and in the service of mankind in US and globally especially in developing countries.

John Anderson, CPA, CISA, CISM, CGEIT, CITP – Chief Financial Officer (CFO)

CPA; held CFO, VP, Controller and senior executive level positions at many reputed corporations including AgaMatrix, Trinity Pharma Solutions, Paratek Pharmaceuticals, Millennium Pharmaceuticals, KPMG among others. Previously performed full service financial work in several industries including High Tech Electronics, eCommerce, Green Industrial, Pharmaceutical and Medical Devices. Given experience at companies in nascent industries, where companies can grow at exeedingly high rates, expert at devising growth plans enabling rapid roll-out of these young companies, enabling their capturing significant portions of their new and expanding markets – and hence the ideal person to lead MedTherapy. Completed undergraduate education at Babson College and subsequent graduate education and advanced trainings at Northeastern University, Suffolk University Law School and Harvard University.

Moran Ben David Shapira, JD, MBA – VP of BD, HR & Legal – VP of Business Development

Rich interdisciplinary background and skills at the cross-section of pharma drug development, biology and business and IP law from blockbuster-drugs IP litigation, to evaluation of new technologies, biological and business opportunities as well as management of collaborations worldwide. Various business strategy positions such as Head of Business Development at Pharma Two B in Israel leadership positions in global strategic partnership and alliance management at GlaxoSmithKline, Novartis, and Takeda in Boston. Established partnerships for early stage innovative projects and clinical development. Before joining the pharmaceutical industry, was a practicing lawyer, specializing in patent litigation for pharmaceutical companies. Holds a BS in Biology from Tel Aviv University, a dual degree from IDC in Finance and Law, and an MBA from Boston University.

Vladimir Slepushkin, MD, PhD – Chief Technology Officer

Global Head of Manufacturing at MedTherapy Biotechnology, leading all functions associated with manufacturing of CAR-T cells and viral vectors. Executive Director of Vector Technology at Autolus Therapeutics, leading process development for manufacturing of lentivirus vectors in suspension cell culture, guiding assay development to support process development for lentiviral vectors, managing CMO for GMP vector production and T-cell processing. Earlier, at Novartis Pharmaceutical, served as Director of CMC, Vector Design and Cell Line Development for CAR-T cancer gene therapy. Was also directing research vector core, and providing lentiviral, retroviral and AAV vectors for Kite Pharma, a CAR-T cell cancer gene therapy company. Developed novel high-quality products by managing diverse technical groups and cross-functional teams, developing first-in-class clinical product from scratch, including facilities, equipment, manufacturing process, quality systems, regulatory CMC submissions and clinical trials design. Proven expertise in technically understanding and leading the development and improvement of cell culture and purification processes, and operations and analytical methods, adhering to customer, regulatory, safety and environmental requirements and guidelines. Identified and resolved regulatory and manufacturing technical problems, as well as intellectual property assessment and licensing. Authored 61 scientific papers in peer- reviewed journals and he’s an author on 14 patents and patent applications. Ph.D. in Molecular Biology, from D.I. Ivanovsky Institute of Virology, Moscow, Russia. M.D. from Moscow Medical Institute, Moscow, Russia

James Blackwell, Ph.D. M.B.A – Head, Manufacturing (CMC)

Greatly accomplished clinical research scientist and executive who has served as President and Principal Consultant, Manager and scientist at many biotech and pharmaceuticals companies including The Windshire Group, Abbott Laboratories, Sanofi Genzyme, Repligen, BioProcess Technology Consultants, Inc. among others. Has long and impressive experience encompassing early process development to commercial operations for development, manufacturing, quality, regulatory, operations, and commercialization. Product experience includes all major therapeutic classes and sub-classes with clients including 1) Stabilityshire service for stability data analysis, reporting, and management; 2) Continued process verification for process and quality monitoring, trending, reporting, and data analysis, 3) RegDocs365 and ARCC (audit ready compliant cloud) quality systems; 4) Learningshire for learning solutions, 5) Assurashire for augmented, virtual quality and technical support through RegDocs365 and ARCC or on site presence. B.S.Ch.E. and MS education at Ohio State University, M.B.A./M.S. at University of Maryland University College, and PhD in Chemical Engineering at Northeastern University

Dr. Eugene V. Barsov, M.D., Ph.D – Director & Head of CAR-T Development

Globally renowned authority on CAR-T cell and gene therapies. Previous work focused upon: Cancer Immunology and Cell Therapy; zinc finger-based artificial transcription factors (ZF-ATF) for CAR-synNotch systems and engineered lentiviral ZF-ATF libraries to enhance cancer-specific T cells; optimizing TSCM-CAR-T expansion and designing safer therapies to mitigate CRS and neurotoxicity.; groundbreaking approach for TSCM-CAR-T expansion and potency for enhanced immunotherapy efficacy; advanced transcriptional and epigenetic strategies to amplify CAR-T tumor-killing efficiency; CRISPR/Cas9 Genome Editing for AIDS Treatment in Non-Human Primate (NHP) Models; Adoptive T Cell Therapy for AIDS Using Engineered NHP T Cells; Immortalization of Human and NHP Antigen-Specific T Cells; and, Hematopoietic Stem Cell Expansion and Genome Editing, among many others. Prior to joining MedTherapy, served in many senior executive and scientist roles at Bristol-Myers Squibb (BMS), Seattle, WA, Kite Pharma, A Gilead Company, Emeryville, CA, Cell Design Labs, Emeryville, CA, Intrexon Corporation, Germantown, MD, and National Laboratory for Cancer Research, Frederick, MD. Completed Postdoctoral Fellowships at  National Cancer Institute, NIH, Frederick, MD; Tampa Bay Research Institute, St. Petersburg, FL; D.I. Ivanovsky Institute of Virology, Academy of Medical Sciences, Moscow, USSR; and Doctor of Philosophy (PhD) in Molecular Biology and Virology at D.I. Ivanovsky Institute of Virology, Academy of Medical Sciences, Moscow, USSR; and M.D., Internal Medicine at I.P. Pavlov First Medical Institute of Leningrad, Leningrad, USSR.

• Lack of adequate funding and investment into the Company
• Unanticipated or currently unknown factors causing supply chain disruption (e.g. COVID)
• Unknown constraints in availability of raw materials
• Competition
• Any other breakthrough advanced technology hitherto unknown
• Sudden burst in demand leading to capacity constraints in the interim
• Employees’ health
• Shortage of highly qualified manpower to be added
• Change in insurance policy coverage which would disallow patients in US to avail of this solution
• IT security breach
• IP violation by others
• Private securities are speculative, illiquid, and carry a high degree of risk – including the loss of the entire investment